Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Ultragenyx Pharmaceutical Inc. - Common Stock
(NQ:
RARE
)
32.02
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 13, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ultragenyx Pharmaceutical Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
July 28, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Beyond The Numbers: 7 Analysts Discuss Ultragenyx Pharmaceutical Stock
July 28, 2025
Via
Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
July 23, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 18, 2025
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
RARE Investors Have Opportunity to Join Ultragenyx Pharmaceutical Inc. Fraud Investigation with the Schall Law Firm
July 18, 2025
From
The Schall Law Firm
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
July 18, 2025
From
Pomerantz LLP
Via
GlobeNewswire
FDA Delays Approval For Ultragenyx's Gene Therapy, But Not A Dealbreaker, Says Analyst
July 14, 2025
Ultragenyx's UX111 gene therapy faces FDA delay due to facility issues; analysts adjust price targets amid uncertain resubmission timeline.
Via
Benzinga
Ultragenyx Pharma Takes Another Hit As FDA Slaps Its Gene Therapy With A Rejection
July 14, 2025
The company has a bigger problem than just the FDA rejection, says one analyst. It's timeline to profitability is now longer.
Via
Investor's Business Daily
Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session
July 14, 2025
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
July 11, 2025
Via
Benzinga
Ultragenyx Receives Complete Response Letter from FDA for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)
July 11, 2025
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Market Monitor News July 11 BMO (Airline stocks UP - Ultragenyx Pharmaceuticals DOWN)
July 11, 2025
Investors shrug off tariff drama as earnings, chip euphoria, and airline optimism steal the show.
Via
Chartmill
Topics
World Trade
Breaking Down Ultragenyx Pharmaceutical: 4 Analysts Share Their Views
July 10, 2025
Via
Benzinga
Let's take a look at the stocks that are in motion in today's session.
July 10, 2025
Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements.
Via
Chartmill
12 Health Care Stocks Moving In Thursday's Intraday Session
July 10, 2025
Via
Benzinga
Crude Oil Down Over 2%; Delta Air Lines Posts Upbeat Earnings
July 10, 2025
Via
Benzinga
Which stocks are experiencing notable movement on Thursday?
July 10, 2025
Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report.
Via
Chartmill
US Stocks Mixed; Initial Jobless Claims Fall
July 10, 2025
Via
Benzinga
Ultragenyx, Mereo Hammered For Their Surprise Miss In Brittle Bone Disease
July 10, 2025
The study will continue onto a third and final analysis toward the end of the year.
Via
Investor's Business Daily
Thursday's session: gap up and gap down stocks
July 10, 2025
Let's have a look at what is happening on the US markets on Thursday. Below you can find the gap up and gap down stocks in today's session.
Via
Chartmill
Ultragenyx, Mereo Shares Dive As Brittle Bone Disease Drug Misses Early Win
July 10, 2025
Ultragenyx shares fall after Phase 3 study misses interim target, but analysts remain positive ahead of final OI data expected later this year.
Via
Benzinga
Get insights into the top gainers and losers of Thursday's pre-market session.
July 10, 2025
Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
Via
Chartmill
12 Health Care Stocks Moving In Thursday's Pre-Market Session
July 10, 2025
Via
Benzinga
Methode Electronics, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
July 10, 2025
Via
Benzinga
Why WK Kellogg Shares Are Trading Higher By Over 50%; Here Are 20 Stocks Moving Premarket
July 10, 2025
Via
Benzinga
Ultragenyx, Mereo Sink After Hours As Bone Drug Trial Continues Without Early Stop; Retail Traders Feel Selloff Is Overdone
July 10, 2025
The companies now expect final data from the Orbit and Cosmic studies by the end of the year.
Via
Stocktwits
12 Health Care Stocks Moving In Wednesday's After-Market Session
July 09, 2025
Via
Benzinga
What's going on in today's after hours session
July 09, 2025
Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session.
Via
Chartmill
Ultragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final Analysis
July 09, 2025
Data from Orbit and Cosmic studies expected around the end of the year
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome
June 27, 2025
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.